• Services
  • Attorneys
  • Media & Insights
  • Online Payment
Results may vary depending on your particular facts and legal circumstances. No aspect of this advertisement has been approved by the Supreme Court of New Jersey. A description of the selection methodology can be found here.
  • Services
  • Attorneys
  • Media & Insights
  • About Us
  • Delivering Value
  • Diversity & Inclusion
  • Meritas
  • Contact Us
  • Online Payment
    A
    Alternative Dispute ResolutionAntitrust & Trade RegulationAppellate Practice
    B
    Banking & Financial ServicesBankruptcy, Creditors’ Rights, and Financial RestructuringBeer LawBusiness Law
    C
    Cannabis LawConstruction LawCooperative and Condominium Law (Co-op & Condo)Criminal Defense
    E
    Economic Development LawElder Care & Special Needs LawElectronic Discovery ("E-Discovery")Environmental LawERISA & Employee BenefitsEstate Planning and Administration & Wealth PreservationExecutive Compensation and Employment Strategies
    F
    Food, Beverage & HospitalityFranchise Law
    H
    Health Care & Life SciencesHealth Care ProvidersHigher EducationHospitals and Health Networks
    I
    ImmigrationInsurance CoverageIntellectual PropertyIntellectual Property Litigation, Arbitration, and Dispute ResolutionIntellectual Property Portfolio Strategy, Management & LicensingInternational BusinessInternet Law
    L
    Labor & EmploymentLiquor Law, Licensing, Manufacturing, and DistributionLitigation
    M
    Media Law & Creative Economy PracticeMergers & AcquisitionsMunicipal Law
    N
    Non-Profit Law
    P
    Patent Preparation and ProsecutionPharmaceutical / Medical Devices / Pharma ServicesProducts and Consumer Liability DefenseProfessional LiabilityPublic Utilities
    R
    Real Estate, Finance, and Land Use
    S
    SecuritiesSolar Energy
    T
    TaxationTelecommunicationsTrademark & Copyright Protection & Enforcement
    V
    Venture Tech & Emerging Growth Companies
    W
    White Collar Investigations & DefenseWorkers’ Compensation
    • New Jersey
    • New York
    • Pennsylvania
    • Blogs
    • Articles
    • Podcasts
    • COVID-19 Resources

    Categories

    Banking Compliance Environmental Food, Beverage & Hospitality General Business Health Care In The News Insurance Labor & Employment Laws Legislation Patents Real Estate Regulatory Tax Trademarks Uncategorized
    Blogs > Legally Grown > Curaleaf Responds to FDA Warning...
    NM PR
    Visit Profile

    Curaleaf Responds to FDA Warning Over CBD Product Marketing

    Curaleaf Responds to FDA Warning Over CBD Product Marketing

    As discussed in our prior blog, on July 22, 2019, the Food and Drug Administration (FDA) issued a Warning Letter to Curaleaf, Inc., in connection with its marketing of certain CBD products. The following day, Curaleaf issued a statement asserting that it was committed to compliance. On July 26, 2019, in advance of the 15-day deadline imposed by the FDA, Curaleaf issued a press release explaining that it had responded to the FDA, informing the agency that it had addressed the issues raised in the Warning Letter.

    Curaleaf’s press release states that it reviewed its website and social media platforms and removed all non-compliant statements identified by the FDA and that some of the products the FDA addressed in its letter had been discontinued. The press release also includes a statement from Curaleaf’s CEO:

    “We care deeply about our customers and making a difference in our industry. Curaleaf is committed to being an ethical and responsible company and working with the FDA to be a leader in our industry, setting the standards and guidelines to best service our customers and the communities we serve.”

    Clearly, Curaleaf has been busy the past few days working to comply with the Warning Letter. We will see if Curaleaf’s quick response will put this matter to rest. Curaleaf’s stock price seemed to stabilize, but only time will tell whether the damage to its relationship with CVS, which publicly announced that it would discontinue sales of Curaleaf’s products in its retail stores after the FDA issued the Warning Letter, can be repaired. Meanwhile, all the other CBD companies out there should be wary of the Warning Letter and ensure that unsubstantiated health claims are not being promoted in conjunction with their products.

    If you have any questions about this post or any other related matters, please feel free to contact our Cannabis Law Practice Group.

    NM PR
    Visit Profile

    Related Posts

    Delta-What??!!- Delta-8 and Delta-9 Create High Anxiety for Policymakers Cannabis Lounges Coming to New Jersey FDA Warns Cannabis Operator Curaleaf About CBD Marketing Claims

    Share

    Tags

    #cannabis law #CBD regulations #FD&C Act

    Helpful links

    • About Us
    • News
    • Services
    • Blogs
    • Attorneys
    • Articles
    • (COVID-19)
    • Award Methodology
    • Events
    • Join our Team
    Connect
    Online Payment

    Connect with Us

    • LinkedIn
    • Facebook
    • Twitter
    • Instagram
    • Youtube

    Join our growing team

    We are looking for quality attorneys to help us do more for our clients. At Norris McLaughlin, each attorney has the same opportunity to succeed whether you’re at the beginning of a career or pinnacle of the profession.

    Learn More

    Subscribe to our content

    Receive timely legal information delivered to your inbox

    This field is for validation purposes and should be left unchanged.
    © , Norris McLaughlin, P.A., All Rights Reserved. Attorney Advertising.
    VIEW OUR DISCLAIMER,  TERMS OF USE,  AND PRIVACY POLICY

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume you consent to our cookie policy. Learn more